Drug Profile


Alternative Names: Anti-MAGE A3 HLA-A-01-restricted TCR; Anti-MAGE-A3-DP4-TCR; Anti-MAGE-A3-TCR

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer Kite Pharma; National Cancer Institute (USA)
  • Class Cell therapies
  • Mechanism of Action Gene transference; MAGEA-3-protein-modulators; T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 03 Oct 2017 Kite Pharma has been acquired by Gilead Sciences
  • 05 Oct 2016 National Cancer Institute reinitiates patient enrolment in a phase-I/II trial in Solid tumours (Second-line therapy or greater, Combination therapy, Late-stage disease) in USA (IV) (NCT02111850)
  • 16 Apr 2016 Interim efficacy data from a phase I/II trial in Solid tumours presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top